Respiratory Syncytial Virus (RSV) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Respiratory Syncytial Virus Infection Clinical Trials Analysis Overview
The report provides an overview of the Respiratory Syncytial Virus (RSV) clinical trial scenario and top-line data relating to the clinical trials on it. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Key Regions | · Asia-Pacific
· Europe · North America · Middle East and Africa · South and Central America |
Key Countries | · The US
· The UK · China · Spain · Japan |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Johnson & Johnson
· GSK plc · AstraZeneca Plc · Pfizer Inc · Sanofi |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Respiratory Syncytial Virus Clinical Trials Segmentation by Regions and Countries
The key regions considered for Respiratory Syncytial Virus clinical trials analysis are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America. North America led the Respiratory Syncytial Virus clinical trials landscape with more than 32% of the clinical trials conducted as of November 2023.
In a country-wise analysis, as of November 2023, the US accounted for the highest number of Respiratory Syncytial Virus clinical trials, followed by the United Kingdom.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the United Kingdom has the highest proportion of Respiratory Syncytial Virus (RSV) Infections to Infectious Disease clinical trials as of November 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey has the highest proportion of Respiratory Syncytial Virus (RSV) Infections in Infectious Disease clinical trials as of November 2023.
Respiratory Syncytial Virus Clinical Trials Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Respiratory Syncytial Virus Clinical Trials
Respiratory Syncytial Virus Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Respiratory Syncytial Virus clinical trials are company, institution, and the government. As of November 2023, the company sponsor type dominated the Respiratory Syncytial Virus clinical trials share, followed by institution.
Respiratory Syncytial Virus Clinical Trials Analysis by Sponsor Type, 2023 (%)
Buy Full Report for More Sponsor Type Insights into Respiratory Syncytial Virus Clinical Trials
Respiratory Syncytial Virus Clinical Trials - Competitive Landscape
Some of the leading sponsors for Respiratory Syncytial Virus clinical trials are:
- Johnson & Johnson
- GSK plc
- AstraZeneca Plc
- Pfizer Inc
- Sanofi
In 2023, Johnson & Johnson conducted the highest number of Respiratory Syncytial Virus clinical trials. It is followed by GSK Plc.
Respiratory Syncytial Virus Clinical Trials Analysis by Sponsors, 2023 (%)
Buy the Full Report to Know More About the Leading Players in Respiratory Syncytial Virus Clinical Trials
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with reason for unaccomplishment.
- The Report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
- Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease
GSK plc
AstraZeneca Plc
Pfizer Inc
Sanofi
ICON Plc
Thermo Fisher Scientific Inc
Novavax Inc
Shanghai Ark Biopharmaceutical Co Ltd
Enanta Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Respiratory Syncytial Virus clinical trials?
North America accounted for the highest number of Respiratory Syncytial Virus clinical trials as of November 2023.
-
Which country conducted the highest number of Respiratory Syncytial Virus clinical trials?
The US conducted the highest number of Respiratory Syncytial Virus clinical trials as of November 2023.
-
Which sponsor type was the most prominent in the Respiratory Syncytial Virus clinical trials?
The company sponsor type was most prominent for Respiratory Syncytial Virus clinical trials.
-
Who are the leading sponsors of Respiratory Syncytial Virus clinical trials?
Some of the leading sponsors of Respiratory Syncytial Virus clinical trials are Johnson & Johnson, GSK plc, AstraZeneca Plc, Pfizer Inc, Sanofi, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.